PHILADELPHIA & LURE, France--(BUSINESS WIRE)--Regulatory News:
Kibow Biotech, Inc. today announced that it has signed an exclusive world-wide licensing and marketing agreement for Kibow Biotics® with Vétoquinol, S.A. (Paris:VETO), a French company specialized in animal health. In exchange, Kibow has received an upfront license fee and will also receive royalties on worldwide sales of its “Kibow Biotics®” product formulation for veterinary applications. The financial terms of this expanded licensing agreement have been held in strict confidence. U.S. and Canadian marketing and distribution rights were sold to Vétoquinol in June 2006.
